Spelling suggestions: "subject:"andtargeting"" "subject:"gentargeting""
1 |
Targeting Metastatic Breast Cancer Using Dual-Ligand NanoparticlesHe, Felicia Jane 30 August 2017 (has links)
No description available.
|
2 |
Development of miRNA-mimic nanoparticles for the treatment of brain tumours / Développement de nanoparticules contenant microARN-mimétique pour le traitement des tumeurs cérébralesAnthiya Ramamoorthi, Shubaash 04 November 2016 (has links)
Les glioblastomes sont des tumeurs cérébrales très agressives présentant une médiane de survie de 15 mois malgré l’usage du traitement de référence. Parmi les stratégies innovantes anti-glioblastome, les microARNs (miARN) constituent de nouvelles cibles et des outils thérapeutiques à fort potentiel. En outre, pour atteindre les cellules tumorales notamment au niveau loco-régional, les miARNs nécessitent d’être administrés grâce à des vecteurs sûrs et efficaces. L’objectif de ce travail a été de développer un système nanoparticulaire original de polyamidoamine réticulé (PAA) capable de véhiculer des miARNs au niveau cellulaire et tissulaire. Dans un premier temps, un test basé sur l’expression de la luciférase a été mis au point afin d’étudier la cytotoxicité et l’efficacité de nanoparticules des miARNs. Dans un second temps,des nanoparticules PAA-miARN ont été développées. Différentes conditions de formulation ont été testées afin d’optimiser la complexation entre miARNs et polymères. En l’absence d’efficacité cellulaire significative des premiers objets obtenus, des modifications du procédé de formulation ont été apportées, permettant une plus grande stabilité et une meilleure efficacité. Une fonctionnalisation par greffage de groupements biotine à des complexes PAA thio-réticulés a amélioré l’efficacité des internalisations. En conclusion, ce travail a permis le développement d’une méthode simple et rapide pour l’évaluation de l’efficacité et de la cytotoxicité de nanoparticules de miARN. La stabilité des nanoparticules a été augmentée par réticulation de thiolet leur internalisation a été améliorée par le greffage,adapté et modulable, d’un ligand cellulaire. / Glioblastoma are aggressive brain tumours with a median survival of 15 months even with the best currently available treatment options. microRNAs (miRNA) are ~23 nucleotide natural silencing RNAs that have great potentials to improve cancer treatment outcomes. Lack of a safe, stable and efficient delivery system has, however, hindered the use of miRNAs inclinical applications. The aim is therefore to develop amiRNA delivery system adapted to glioblastoma using linear chain cationic polyamidoamine (PAA) polymers.The first part involved the development of luciferase assay that combined the measurement of gene-knockdown efficiency and cytotoxicity of miRNA nanoparticles. The simple two-step procedure was more effective and sensitive compared to the conventional protein-based normalization method. The second part was focused on the development of miRNA nanoparticles. In the initial phase, conditions required for maximum miRNA-polymer binding was achieved, however, the newly developed miRNA-PAA nanoparticlesdid not produce significant functional gene-knockdown after cell treatment. The second stage was focused on the optimization of nanoparticle formulation as a function of stability in physiologicalionic concentration. Stable PAA-nanoparticles displaying moderate cellular uptake and gene-knockdown were obtained. The final stage of development was focused on PAA-nanoparticle tagging with biotin, which improved their cellular uptake. This work developed simple and informative luciferase assay ; the stability of miRNA-PAA-nanoparticles was improved by thiol-crosslinking and the functional performance was strongly enhanced by a simple butsmart method of ligand tagging.
|
3 |
DESIGN, SYNTHESIS, AND PRECLINICAL EVALUATION OF LIGAND-TARGETED CONJUGATES FOR CANCER RADIOTHERANOSTICSSpencer D Lindeman (11205204) 29 July 2021 (has links)
For any drug candidate to be approved by the U.S. Food and Drug Administration, it must meet strict standards for safety and efficacy. While the field of nuclear medicine is over 100 years old, traditional methods such as external beams or systematic administration have rarely met these standards or have limited application. Ligand-targeted therapy and diagnostics, or “theranostics,” has emerged in the past several decades as an exciting field that offers new possibilities to design drugs that are both safe and effective. When applied to nuclear medicine, the field of ligand-targeted radioactive theranostics is younger still, with many critical lessons being discovered and applied currently. This dissertation outlines the necessary principles of radioactive theranostic drug design, then demonstrates the application of several more recent techniques to improve both the efficacy and safety of radioactive theranostics targeting two high priority oncological targets: fibroblast activation protein alpha and folate receptor.
|
Page generated in 0.0782 seconds